

Leda L Talib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/414496/publications.pdf>

Version: 2024-02-01

58
papers

2,525
citations

257101

24
h-index

197535

49
g-index

72
all docs

72
docs citations

72
times ranked

4432
citing authors

#	ARTICLE	IF	CITATIONS
1	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
2	Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2011, 198, 351-356.	1.7	319
3	Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels. <i>Current Alzheimer Research</i> , 2014, 11, 799-805.	0.7	150
4	Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. <i>Journal of Psychiatric Research</i> , 2014, 50, 36-41.	1.5	135
5	Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 115-121.	1.8	119
6	Increased phospholipase A2 activity in schizophrenia with absent response to niacin. <i>Schizophrenia Research</i> , 2003, 61, 1-6.	1.1	104
7	Clinical and biological effects of long-term lithium treatment in older adults with amnesic mild cognitive impairment: randomised clinical trial. <i>British Journal of Psychiatry</i> , 2019, 215, 668-674.	1.7	91
8	Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2011, 45, 220-224.	1.5	88
9	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 455-463.	1.2	77
10	Reduced serum levels of adiponectin in elderly patients with major depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 1081-1085.	1.5	74
11	Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e672-e678.	1.1	67
12	Reduced Serum Nerve Growth Factor in Patients With Late-Life Depression. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 493-496.	0.6	65
13	Interleukin-1 β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 172-176.	0.6	62
14	Circulating Glial-derived neurotrophic factor is reduced in late-life depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 135-139.	1.5	58
15	Reduced Cerebrospinal Fluid Levels of Brain-Derived Neurotrophic Factor Is Associated With Cognitive Impairment in Late-Life Major Depression. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2014, 69, 845-851.	2.4	54
16	Clinical and biological predictors of Alzheimer's disease in patients with amnesic mild cognitive impairment. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 216-222.	0.9	49
17	Lithium increases platelet serine-9 phosphorylated GSK-3 β levels in drug-free bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , 2015, 62, 78-83.	1.5	47
18	Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 815-819.	1.4	43

#	ARTICLE	IF	CITATIONS
19	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 431-441.	0.9	42
20	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 330-356.	1.3	33
21	Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. <i>Bipolar Disorders</i> , 2016, 18, 63-70.	1.1	32
22	Platelet biomarkers in Alzheimer's disease. <i>World Journal of Psychiatry</i> , 2012, 2, 95.	1.3	30
23	Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2017, 29, 949-958.	0.6	27
24	Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2014, 121, 193-200.	1.4	26
25	Inhibition of platelet phospholipase A2 activity by catuaba extract suggests anti-inflammatory properties. <i>Phytotherapy Research</i> , 2004, 18, 942-944.	2.8	25
26	Cognitive training increases platelet PLA2 activity in healthy elderly subjects. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008, 78, 265-269.	1.0	25
27	Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. <i>Journal of Neural Transmission</i> , 2015, 122, 1371-1380.	1.4	22
28	Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. <i>Journal of Psychiatric Research</i> , 2011, 45, 1617-1620.	1.5	20
29	Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 1053-1058.	1.5	20
30	Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 701-706.	1.8	19
31	Hippocampal serotonin depletion is related to the presence of generalized tonic-clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy. <i>Epilepsy Research</i> , 2015, 111, 18-25.	0.8	18
32	Kynurenine is correlated with IL-1 ² in plasma of schizophrenia patients. <i>Journal of Neural Transmission</i> , 2018, 125, 869-873.	1.4	18
33	Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 190-196.	1.3	18
34	Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 128-135.	0.9	18
35	Inhibition of phospholipase A2 increases Tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2010, 82, 57-60.	1.0	15
36	Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimer's disease patients. <i>Revista De Psiquiatria Clinica</i> , 2019, 46, 120-124.	0.6	15

#	ARTICLE	IF	CITATIONS
37	Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons. <i>Molecules</i> , 2015, 20, 19878-19885.	1.7	14
38	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 501-507.	1.8	13
39	Is cerebral microbleed prevalence relevant as a biomarker in amnesic mild cognitive impairment and mild Alzheimer's disease?. <i>Neuroradiology Journal</i> , 2017, 30, 477-485.	0.6	12
40	A radioenzymatic assay to identify three groups of phospholipase A2 in platelets. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 86, 149-153.	1.0	10
41	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 483-488.	1.8	10
42	Cognitive impairment in remitted late-life depression is not associated with Alzheimer's disease-related CSF biomarkers. <i>Journal of Affective Disorders</i> , 2020, 272, 409-416.	2.0	10
43	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: An updated systematic review and meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 24-33.	1.3	10
44	Reduced Annexin A3 in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 489-494.	1.8	9
45	Glycogen synthase kinase-3 β in patients with bipolar I disorder: results from a prospective study. <i>Bipolar Disorders</i> , 2016, 18, 334-341.	1.1	8
46	Correlation between platelet and brain PLA2 activity. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 265-268.	1.0	7
47	Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 479-484.	0.9	6
48	Plasma metabolites in first episode psychoses. <i>Schizophrenia Research</i> , 2019, 206, 468-470.	1.1	6
49	AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 659-667.	1.2	6
50	Plasmatic endocannabinoids are decreased in subjects with ultra-high risk of psychosis. <i>European Journal of Neuroscience</i> , 2022, 55, 1079-1087.	1.2	5
51	Increased platelet glycogen synthase kinase 3beta in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 195, 402-405.	1.1	4
52	Plasma Metabolite Profiles in First Episode Psychosis: Exploring Symptoms Heterogeneity/Severity in Schizophrenia and Bipolar Disorder Cohorts. <i>Frontiers in Psychiatry</i> , 2020, 11, 496.	1.3	4
53	Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 949-962.	1.2	4
54	Increased CSF levels of total Tau in patients with subcortical cerebrovascular pathology and cognitive impairment. <i>Dementia E Neuropsychologia</i> , 2017, 11, 419-425.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Increased PLA2 activity in individuals at ultra-high risk for psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1593-1599.	1.8	2
56	COX-2 pathway is upregulated in ultra-high risk individuals for psychosis. World Journal of Biological Psychiatry, 2022, 23, 236-241.	1.3	2
57	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P49.	1.4	0
58	Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clinical and Translational Allergy, 2014, 4, P118.	1.4	0